Advertisement

Galectin and Immune System: Toward Clinical Applications

  • Mitsuomi Hirashima

Abstract

We first cloned galectin-9 (Gal-9) as a T cell-derived eosinophil chemoattractant. Gal-9 plays a role in not only accumulation but also activation of eosinophils in experimental allergic models and human allergic patients, because Gal-9 induces eosinophil chemoattraction in vitro and in vivo and activates eosinophils in many aspects (Matsumoto et al. 1998). However, Gal-9 also has other functions, such as cell differentiation, aggregation, adhesion, and cell death, than eosinophil chemoattraction and activation (Kashio et al. 2003; Dai et al. 2005). For example, in patients with malignant tumor, such as malignant melanoma and breast cancer, high Gal-9 expression in tumor cells links to better clinical features in tumor-bearing patients (Kageshita et al. 2002; Irie et al. 2005). From the above findings, we have established Galpharma, a Bio-Venture company to develop the method for predicting tumor metastasis, especially for breast cancer.

Keywords

Treg Cell Synovial Cell Pannus Formation Treg Cell Differentiation Synovial Cell Proliferation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dai S-Y, Nakagawa R, Itoh A, Murakami H, Kashio Y, Abe H, Katoh S, Kontani K, Kihara M, Zhang SL, Hata T, Nakamura T, Yamauchi A, Hirashima M (2005) Galectin-9 induces maturation of human monocyte-derived dendritic cells. J Immunol 175:2974–2981PubMedGoogle Scholar
  2. Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y, Seki M, Nishi N, Nakamura T, Yokomise H, Hirashima M (2005) Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res 11:2962–2968PubMedCrossRefGoogle Scholar
  3. Kageshita T, Kashio Y, Yamauchi A, Seki M, Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T, Hirashima M (2002) Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer 99(6):809–816PubMedCrossRefGoogle Scholar
  4. Kashio Y, Nakamura K, Abedin MJ, Seki M, Nishi N, Yoshida N, Nakamura T, Hirashima M (2003) Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol 170:3631–3636PubMedGoogle Scholar
  5. Katoh S, Nobumoto A, Ishii N, Takeshita K, Dai S-Y, Shinonaga R, Niki T, Nishi N, Tominaga A, Yamauchi A, Hirashima M (2007) Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. AJRCCM (in press)Google Scholar
  6. Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S, Stevens RL, Hirashima M (1998) Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem 273:16976–16984PubMedCrossRefGoogle Scholar
  7. Nishi N, Itoh A, Fujiyama A, Yoshida N, Araya S, Hirashima M, Shoji H, Nakamura T (2005) Development of highly stable galectins: truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett 579:2058–2064PubMedCrossRefGoogle Scholar
  8. Tsuboi Y, Abe H, Nakagawa R, Oomizu S, Watanabe K, Nishi N, Nakamura T, Yamauchi A, Hirashima M (2007) Galectin-9 protects mice from Shwartzman reacting prostaglandin E2-producing polymorphonuclear leukocytes. Clin Immunol (in press)Google Scholar
  9. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Storm TB, Kuchroo VK (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6(12):1245–1252PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Mitsuomi Hirashima
    • 1
  1. 1.Department of Immunology and Immunopathology, Faculty of MedicineKagawa UniversityKagawaJapan

Personalised recommendations